Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder
What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression...
Saved in:
| Published in | BJU international Vol. 109; no. 11; pp. 1716 - 1726 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.06.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | What's known on the subject? and What does the study add?
Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non‐neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients’ outcomes.
OBJECTIVE
•
To assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear.
PATIENTS AND METHODS
•
We investigated the expression of AR, ERα and ERβ in 188 bladder tumour specimens, as well as matched 141 non‐neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry.
•
We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort.
RESULTS
•
AR/ERα/ERβ was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours.
•
Significantly lower expression of AR/ERα was found in high‐grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low‐grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively.
•
Significantly higher expression of ERβ was found in high‐grade tumours (58%) and tumours invading muscularis propria (67%) compared to low‐grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively.
•
Kaplan–Meier and log‐rank tests further showed that positivity of ERβ (but not AR or ERα) was associated with the recurrence of low‐grade tumours (P= 0.0072); the progression of low‐grade tumours (P= 0.0005), high‐grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease‐specific mortality in patients with tumours invading muscularis propria (P= 0.0073).
CONCLUSIONS
•
Compared to benign bladders, a significant decrease in the expression of AR, ERα or ERβ in bladder cancer was seen.
•
Loss of AR or ERα was strongly associated with higher grade/more invasive tumours, whereas ERβ expression was increased in high‐grade/invasive tumours and predicted a worse prognosis. |
|---|---|
| AbstractList | What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non-neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes. OBJECTIVE * To assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear. PATIENTS AND METHODS * We investigated the expression of AR, ER[alpha] and ER[beta] in 188 bladder tumour specimens, as well as matched 141 non-neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry. * We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort. RESULTS * AR/ER[alpha]/ER[beta] was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours. * Significantly lower expression of AR/ER[alpha] was found in high-grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low-grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively. * Significantly higher expression of ER[beta] was found in high-grade tumours (58%) and tumours invading muscularis propria (67%) compared to low-grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively. * Kaplan-Meier and log-rank tests further showed that positivity of ER[beta] (but not AR or ER[alpha]) was associated with the recurrence of low-grade tumours (P= 0.0072); the progression of low-grade tumours (P= 0.0005), high-grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease-specific mortality in patients with tumours invading muscularis propria (P= 0.0073). CONCLUSIONS * Compared to benign bladders, a significant decrease in the expression of AR, ER[alpha] or ER[beta] in bladder cancer was seen. * Loss of AR or ER[alpha] was strongly associated with higher grade/more invasive tumours, whereas ER[beta] expression was increased in high-grade/invasive tumours and predicted a worse prognosis. [PUBLICATION ABSTRACT] What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non‐neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients’ outcomes. OBJECTIVE • To assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear. PATIENTS AND METHODS • We investigated the expression of AR, ERα and ERβ in 188 bladder tumour specimens, as well as matched 141 non‐neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry. • We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort. RESULTS • AR/ERα/ERβ was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours. • Significantly lower expression of AR/ERα was found in high‐grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low‐grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively. • Significantly higher expression of ERβ was found in high‐grade tumours (58%) and tumours invading muscularis propria (67%) compared to low‐grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively. • Kaplan–Meier and log‐rank tests further showed that positivity of ERβ (but not AR or ERα) was associated with the recurrence of low‐grade tumours (P= 0.0072); the progression of low‐grade tumours (P= 0.0005), high‐grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease‐specific mortality in patients with tumours invading muscularis propria (P= 0.0073). CONCLUSIONS • Compared to benign bladders, a significant decrease in the expression of AR, ERα or ERβ in bladder cancer was seen. • Loss of AR or ERα was strongly associated with higher grade/more invasive tumours, whereas ERβ expression was increased in high‐grade/invasive tumours and predicted a worse prognosis. What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non-neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes. To assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear. We investigated the expression of AR, ERα and ERβ in 188 bladder tumour specimens, as well as matched 141 non-neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry. We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort. AR/ERα/ERβ was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours. Significantly lower expression of AR/ERα was found in high-grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low-grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively. Significantly higher expression of ERβ was found in high-grade tumours (58%) and tumours invading muscularis propria (67%) compared to low-grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively. Kaplan-Meier and log-rank tests further showed that positivity of ERβ (but not AR or ERα) was associated with the recurrence of low-grade tumours (P= 0.0072); the progression of low-grade tumours (P= 0.0005), high-grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease-specific mortality in patients with tumours invading muscularis propria (P= 0.0073). Compared to benign bladders, a significant decrease in the expression of AR, ERα or ERβ in bladder cancer was seen. Loss of AR or ERα was strongly associated with higher grade/more invasive tumours, whereas ERβ expression was increased in high-grade/invasive tumours and predicted a worse prognosis. What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non-neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes.UNLABELLEDWhat's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour progression. The expression of androgen and/or oestrogen receptors has been assessed in bladder cancer, leading to conflicting data of expression levels and their relationship to histopathological characteristics of the tumours. We simultaneously analyze three receptors in non-neoplastic bladder tissues as well as in primary and metastatic bladder tumour specimens. Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes.To assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear.OBJECTIVETo assess the expression of the androgen receptor (AR) and oestrogen receptors (ERs) in bladder tumours because recent studies have shown conflicting results and the prognostic significance of their expression remains unclear.We investigated the expression of AR, ERα and ERβ in 188 bladder tumour specimens, as well as matched 141 non-neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry. We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort.PATIENTS AND METHODSWe investigated the expression of AR, ERα and ERβ in 188 bladder tumour specimens, as well as matched 141 non-neoplastic bladder and 14 lymph node metastasis tissues, by immunohistochemistry. We then evaluated the relationships between their expression and the clinicopathological features available for the present patient cohort.AR/ERα/ERβ was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours. Significantly lower expression of AR/ERα was found in high-grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low-grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively. Significantly higher expression of ERβ was found in high-grade tumours (58%) and tumours invading muscularis propria (67%) compared to low-grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively. Kaplan-Meier and log-rank tests further showed that positivity of ERβ (but not AR or ERα) was associated with the recurrence of low-grade tumours (P= 0.0072); the progression of low-grade tumours (P= 0.0005), high-grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease-specific mortality in patients with tumours invading muscularis propria (P= 0.0073).RESULTSAR/ERα/ERβ was positive in 80%/50%/89% of benign urothelium, 50%/67%/41% of benign stroma, 42%/27%/49% of primary tumours and 71%/64%/71% of metastatic tumours. Significantly lower expression of AR/ERα was found in high-grade tumours (36%/23%) and tumours invading muscularis propria (33%/19%) compared to low-grade tumours (55%; P= 0.0232/38%; P= 0.0483) and tumours not invading muscularis propria (51%; P= 0.0181/35%; P= 0.0139), respectively. Significantly higher expression of ERβ was found in high-grade tumours (58%) and tumours invading muscularis propria (67%) compared to low-grade tumours (29%; P= 0.0002) and tumours not invading muscularis propria (34%; P < 0.0001), respectively. Kaplan-Meier and log-rank tests further showed that positivity of ERβ (but not AR or ERα) was associated with the recurrence of low-grade tumours (P= 0.0072); the progression of low-grade tumours (P= 0.0005), high-grade tumours not invading muscularis propria (P= 0.0020) and tumours invading muscularis propria (P= 0.0010); or disease-specific mortality in patients with tumours invading muscularis propria (P= 0.0073).Compared to benign bladders, a significant decrease in the expression of AR, ERα or ERβ in bladder cancer was seen. Loss of AR or ERα was strongly associated with higher grade/more invasive tumours, whereas ERβ expression was increased in high-grade/invasive tumours and predicted a worse prognosis.CONCLUSIONSCompared to benign bladders, a significant decrease in the expression of AR, ERα or ERβ in bladder cancer was seen. Loss of AR or ERα was strongly associated with higher grade/more invasive tumours, whereas ERβ expression was increased in high-grade/invasive tumours and predicted a worse prognosis. |
| Author | Izumi, Koji Yao, Jorge L. Netto, George J. Miyamoto, Hiroshi Hsu, Iawen Messing, Edward M. Chaux, Alcides Yeh, Shuyuan Chang, Chawnshang Zheng, Yichun |
| Author_xml | – sequence: 1 givenname: Hiroshi surname: Miyamoto fullname: Miyamoto, Hiroshi – sequence: 2 givenname: Jorge L. surname: Yao fullname: Yao, Jorge L. – sequence: 3 givenname: Alcides surname: Chaux fullname: Chaux, Alcides – sequence: 4 givenname: Yichun surname: Zheng fullname: Zheng, Yichun – sequence: 5 givenname: Iawen surname: Hsu fullname: Hsu, Iawen – sequence: 6 givenname: Koji surname: Izumi fullname: Izumi, Koji – sequence: 7 givenname: Chawnshang surname: Chang fullname: Chang, Chawnshang – sequence: 8 givenname: Edward M. surname: Messing fullname: Messing, Edward M. – sequence: 9 givenname: George J. surname: Netto fullname: Netto, George J. – sequence: 10 givenname: Shuyuan surname: Yeh fullname: Yeh, Shuyuan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25918772$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22221549$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU2LFDEQhoOsuB_6FyQggpdpk-50T3IRdFl1ZcGLC95COl1ZM2SSMenGWfDHWz0fLuxpc0ml6knlTb3n5CSmCIRQziqO6_2q4qITC8HZz6pmnFecLVlXbZ-Rs_-Fk2PMVHdKzktZMYaJrn1BTmtcvBXqjPy92m4ylOJTpMlRE4ec7iDOAU1Qxv0pg4XNmHLZ5f1Y6AYLMZXRW1r8XfTOWxMtUB_plNP4C4I3gUZIm2DKem6NOSz5aPI97YMZBsgvyXNnQoFXh_2C3H6--nH5dXHz_cv15cebhRW17BaOQ61UzSVrVN1I1cmub4xwyrY9CmvlUAMDOwjX961qeyl6ZRQzIMHJmrnmgrzb90XVvyf8lV77YiEEgwKnojmOUIpOLQWibx6hqzTliOo0b9qmEaoVDVKvD9TUr2HQm-zX-C99nCsCbw-AKdYEl3E4vjxwreJyuayR-7DnbE6lZHDa-tGM6MaYjQ-oTM-G65WevdSzr3o2XO8M11tsIB81OL7xhKuHt__4APdPvqc_fbvdhc0_YLPEDg |
| CODEN | BJINFO |
| CitedBy_id | crossref_primary_10_1038_s41419_019_1827_3 crossref_primary_10_1016_j_urolonc_2018_03_020 crossref_primary_10_1002_cam4_1979 crossref_primary_10_18632_oncotarget_2851 crossref_primary_10_3233_BLC_160052 crossref_primary_10_1093_ilar_ilu018 crossref_primary_10_3892_ijo_2016_3781 crossref_primary_10_1016_j_clgc_2016_05_017 crossref_primary_10_23736_S2724_6051_20_03646_2 crossref_primary_10_3390_cancers12082155 crossref_primary_10_1007_s00345_020_03358_x crossref_primary_10_23736_S2724_6051_19_03563_X crossref_primary_10_18632_aging_103523 crossref_primary_10_1007_s12672_012_0123_9 crossref_primary_10_1038_s41385_022_00549_0 crossref_primary_10_1007_s10552_019_1131_7 crossref_primary_10_1016_j_juro_2014_04_101 crossref_primary_10_1016_j_urolonc_2019_01_023 crossref_primary_10_1530_ERC_15_0209 crossref_primary_10_1016_j_canlet_2018_03_045 crossref_primary_10_1093_carcin_bgt348 crossref_primary_10_3390_ijms241814374 crossref_primary_10_18632_oncotarget_7358 crossref_primary_10_1038_nrurol_2013_53 crossref_primary_10_11603_2414_4533_2019_3_10550 crossref_primary_10_1177_0300060521996929 crossref_primary_10_1016_j_ijso_2023_100645 crossref_primary_10_1038_nrurol_2015_232 crossref_primary_10_1186_s13293_018_0204_8 crossref_primary_10_1016_j_eururo_2013_01_005 crossref_primary_10_1593_tlo_13247 crossref_primary_10_3390_ijms19030777 crossref_primary_10_1038_s41585_023_00806_2 crossref_primary_10_1177_1066896918814198 crossref_primary_10_4103_iju_IJU_320_19 crossref_primary_10_1016_j_urolonc_2020_04_022 crossref_primary_10_1097_PAP_0000000000000150 crossref_primary_10_1038_bjc_2017_393 crossref_primary_10_1016_j_urolonc_2019_03_008 crossref_primary_10_18632_oncotarget_1421 crossref_primary_10_18632_oncotarget_5467 crossref_primary_10_1007_s11255_014_0834_7 crossref_primary_10_62347_MNYA9065 crossref_primary_10_1007_s12020_012_9762_4 crossref_primary_10_1016_j_euros_2022_06_007 crossref_primary_10_1111_apm_13183 crossref_primary_10_1016_j_jfda_2017_06_006 crossref_primary_10_1016_j_clgc_2017_09_016 crossref_primary_10_1016_j_euf_2019_04_021 crossref_primary_10_3390_cancers16040746 crossref_primary_10_1002_mc_21978 crossref_primary_10_1371_journal_pone_0174746 crossref_primary_10_1007_s00262_016_1945_z crossref_primary_10_1002_1878_0261_12377 crossref_primary_10_1097_MOU_0000000000000092 crossref_primary_10_1038_s41388_023_02876_3 crossref_primary_10_1016_j_lfs_2017_09_029 crossref_primary_10_1097_01_XEJ_0000508564_83493_20 crossref_primary_10_3390_ijms140612346 crossref_primary_10_1016_j_urolonc_2013_04_010 crossref_primary_10_1111_bju_12014 crossref_primary_10_4103_iju_iju_150_24 crossref_primary_10_3389_fendo_2021_684140 crossref_primary_10_1038_s41585_023_00761_y crossref_primary_10_1210_endocr_bqad071 crossref_primary_10_1186_s12885_019_5512_9 crossref_primary_10_3389_fendo_2021_643870 crossref_primary_10_1016_j_urolonc_2021_06_021 crossref_primary_10_18632_oncotarget_20043 crossref_primary_10_1007_s11255_015_0980_6 crossref_primary_10_1016_j_envres_2020_110485 crossref_primary_10_1016_j_fjurol_2024_102723 crossref_primary_10_1080_21681805_2023_2166103 crossref_primary_10_1038_s12276_018_0155_5 crossref_primary_10_3390_nu15194165 crossref_primary_10_1007_s00428_018_2354_9 crossref_primary_10_1016_j_critrevonc_2013_08_008 crossref_primary_10_1016_j_path_2015_08_002 crossref_primary_10_1002_mgg3_1233 crossref_primary_10_18632_oncotarget_5007 crossref_primary_10_18632_oncotarget_8756 crossref_primary_10_4161_cbt_27631 crossref_primary_10_1007_s13629_014_0070_z crossref_primary_10_1016_j_humpath_2012_02_011 crossref_primary_10_1080_14728222_2017_1280468 crossref_primary_10_3390_cancers10120484 crossref_primary_10_1016_j_canlet_2014_03_018 crossref_primary_10_1016_j_tranon_2018_02_001 crossref_primary_10_1038_nrurol_2016_84 crossref_primary_10_1186_s13104_025_07128_z crossref_primary_10_18632_oncotarget_10679 crossref_primary_10_3892_mco_2017_1389 crossref_primary_10_1309_AJCPU8UCEZYG4WTV crossref_primary_10_1007_s13577_019_00255_3 crossref_primary_10_1136_jclinpath_2013_201586 crossref_primary_10_1155_2015_840640 crossref_primary_10_1007_s00432_023_05348_z crossref_primary_10_1038_s41419_020_2486_0 crossref_primary_10_1002_mc_23783 crossref_primary_10_1016_j_juro_2012_05_079 crossref_primary_10_1016_j_euf_2020_10_002 crossref_primary_10_1038_s41419_019_1581_6 crossref_primary_10_3109_00365513_2013_818706 crossref_primary_10_1186_s12301_019_0014_1 crossref_primary_10_3892_ol_2018_8837 crossref_primary_10_3390_cancers13050975 crossref_primary_10_1016_j_labinv_2023_100148 crossref_primary_10_1016_j_tice_2024_102416 crossref_primary_10_1002_cncr_30027 crossref_primary_10_1007_s10528_024_10854_x crossref_primary_10_1371_journal_pone_0148851 crossref_primary_10_1210_me_2015_1128 crossref_primary_10_1038_s41572_023_00468_9 crossref_primary_10_1111_iju_13841 crossref_primary_10_1016_j_urolonc_2022_09_012 crossref_primary_10_1016_j_tranon_2017_01_012 crossref_primary_10_3892_ijo_2012_1593 crossref_primary_10_1016_j_tranon_2017_01_013 crossref_primary_10_1016_j_eururo_2013_07_040 crossref_primary_10_3109_10408363_2015_1033610 crossref_primary_10_1007_s12253_018_0431_7 crossref_primary_10_1016_j_euf_2017_08_007 crossref_primary_10_3389_fendo_2018_00706 crossref_primary_10_3892_or_2013_2416 crossref_primary_10_1097_MOU_0000000000000606 crossref_primary_10_3390_biomedicines12050957 crossref_primary_10_1007_s00345_024_05166_z crossref_primary_10_1007_s12672_024_00902_8 crossref_primary_10_1016_j_humpath_2017_04_003 crossref_primary_10_3389_fonc_2021_784627 crossref_primary_10_1007_s00345_013_1037_z crossref_primary_10_1038_s41568_020_00313_1 crossref_primary_10_1016_j_ajur_2020_05_011 crossref_primary_10_3892_ol_2019_11080 crossref_primary_10_1186_s13063_020_04283_5 crossref_primary_10_3390_cells10051169 crossref_primary_10_1016_j_mce_2017_06_021 crossref_primary_10_1016_j_cbi_2023_110840 crossref_primary_10_1158_1535_7163_MCT_17_0786 crossref_primary_10_3349_ymj_2014_55_5_1214 crossref_primary_10_1007_s00428_018_2496_9 crossref_primary_10_1016_j_ejso_2023_107034 crossref_primary_10_18632_oncotarget_8024 crossref_primary_10_3390_ijms221810030 crossref_primary_10_1016_j_eururo_2015_08_037 crossref_primary_10_1016_j_urolonc_2017_06_043 crossref_primary_10_18632_oncotarget_9994 crossref_primary_10_4081_aiua_2023_11514 crossref_primary_10_1016_j_euo_2023_02_011 crossref_primary_10_1080_15384047_2016_1235667 crossref_primary_10_1002_nau_23041 crossref_primary_10_1007_s00345_013_1035_1 crossref_primary_10_3892_or_2015_4220 crossref_primary_10_1007_s12672_024_01324_2 crossref_primary_10_4103_iju_iju_324_23 crossref_primary_10_1016_j_ajpath_2013_01_018 crossref_primary_10_1080_13685538_2020_1808968 crossref_primary_10_3390_cancers9020020 crossref_primary_10_1016_j_clgc_2015_04_001 |
| Cites_doi | 10.1111/j.1365-2559.2004.01841.x 10.1093/jnci/djk113 10.1016/j.eururo.2009.06.032 10.1016/S0302-2838(02)00038-6 10.1002/(SICI)1096-9896(1998100)186:2<165::AID-PATH155>3.0.CO;2-Y 10.1111/j.1440-1827.2009.02477.x 10.1016/S0022-5347(05)66041-7 10.3322/caac.20073 10.1002/cncr.23986 10.1038/modpathol.2008.34 10.1055/s-2002-35951 10.1186/1471-2490-8-7 10.1677/ERC-08-0124 10.1530/ERC-11-0010 10.1677/erc.1.01255 10.1111/j.1743-6109.2010.01811.x 10.1016/0090-4295(85)90534-5 10.1002/cncr.21945 10.1111/j.1464-410X.2010.09834.x 10.1002/cncr.25502 10.1046/j.1365-2559.1997.5610801.x 10.1016/j.urology.2009.10.041 10.1016/j.urology.2004.03.025 10.1074/jbc.M202852200 10.1016/j.urology.2007.02.041 10.1016/j.urolonc.2009.01.033 10.1016/0090-4295(86)90073-7 10.1111/j.1442-2042.2010.02603.x 10.5858/2005-129-194-EREIPU 10.1158/0008-5472.CAN-05-3530 10.1016/j.urolonc.2010.04.003 |
| ContentType | Journal Article |
| Copyright | 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL 2015 INIST-CNRS 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
| Copyright_xml | – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
| DOI | 10.1111/j.1464-410X.2011.10706.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 1726 |
| ExternalDocumentID | 2975456831 22221549 25918772 10_1111_j_1464_410X_2011_10706_x BJU10706 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
| ID | FETCH-LOGICAL-c4286-f1e2992180392389686b3a4f9c5bece58d2e0ecd4fbb595b84b9a90ae8ef820f3 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Fri Jul 11 07:24:58 EDT 2025 Sun Jul 13 04:34:41 EDT 2025 Mon Jul 21 06:04:48 EDT 2025 Mon Jul 21 09:15:10 EDT 2025 Tue Jul 01 03:49:54 EDT 2025 Thu Apr 24 23:02:30 EDT 2025 Wed Jan 22 16:51:50 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Immunohistochemistry Estrogen receptor Nephrology Relapse Urinary system disease Prognosis progression Urinary tract disease Urinary tract oestrogen receptor Bladder tumor Urology recurrence Anatomic pathology Urinary system Urinary bladder Androgen receptor Evolution Bladder disease bladder tumour Hormonal receptor Urothelium |
| Language | English |
| License | CC BY 4.0 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4286-f1e2992180392389686b3a4f9c5bece58d2e0ecd4fbb595b84b9a90ae8ef820f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22221549 |
| PQID | 1353349543 |
| PQPubID | 1026371 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1011846974 proquest_journals_1353349543 pubmed_primary_22221549 pascalfrancis_primary_25918772 crossref_citationtrail_10_1111_j_1464_410X_2011_10706_x crossref_primary_10_1111_j_1464_410X_2011_10706_x wiley_primary_10_1111_j_1464_410X_2011_10706_x_BJU10706 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2012 |
| PublicationDateYYYYMMDD | 2012-06-01 |
| PublicationDate_xml | – month: 06 year: 2012 text: June 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
| References | 2001; 166 2002; 36 2004; 64 2010; 17 2002; 12 1984; 44 2004; 45 2008; 15 2008; 8 2007; 99 2011; 18 2009; 115 2010; 60 1985; 25 2009; 56 2011; 108 2009; 75 2002; 41 2010; 116 2010; 28 2006; 66 1997; 30 2005; 129 1986; 28 2008; 21 2006; 106 2011; 29 2010; 7 2009; 16 2007; 69 1998; 186 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_10_2 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 Reid LM (e_1_2_7_31_2) 1984; 44 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_23_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_21_2 e_1_2_7_33_2 e_1_2_7_20_2 Croft PR (e_1_2_7_16_2) 2005; 129 |
| References_xml | – volume: 108 start-page: 24 year: 2011 end-page: 30 article-title: Loss of androgen receptor expression is not associated with pathological grade, stage, gender or outcome in bladder cancer: a large multi‐institutional study publication-title: BJU Int – volume: 56 start-page: 1093 year: 2009 end-page: 5 article-title: Estrogen and progesterone hormone receptor expression in urothelial carcinoma of the bladder publication-title: Eur Urol – volume: 66 start-page: 1337 year: 2006 end-page: 45 article-title: Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment publication-title: Cancer Res – volume: 75 start-page: 820 year: 2009 end-page: 7 article-title: Androgen receptor is a potential therapeutic target for bladder cancer publication-title: Urology – volume: 116 start-page: 5517 year: 2010 end-page: 26 article-title: Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy publication-title: Cancer – volume: 45 start-page: 98 year: 2004 end-page: 9 article-title: The androgen receptor revisited in urothelial carcinoma publication-title: Histopathology – volume: 12 start-page: 312 year: 2002 end-page: 7 article-title: The sex hormone receptors in the bladder in childhood – I. Preliminary report in male subjects publication-title: Eur J Pediatr Surg – volume: 60 start-page: 1 year: 2010 end-page: 8 article-title: Non‐invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system publication-title: Pathol Int – volume: 7 start-page: 2698 year: 2010 end-page: 713 article-title: Sex steroid receptors in male human bladder: expression and biological function publication-title: J Sex Med – volume: 18 start-page: 451 year: 2011 end-page: 64 article-title: Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor‐positive bladder cancer cells publication-title: Endocr Relat Cancer – volume: 21 start-page: S8 year: 2008 end-page: 15 article-title: Current issues in ER and HER2 testing by IHC in breast cancer publication-title: Mod Pathol – volume: 15 start-page: 351 year: 2008 end-page: 64 article-title: Roles of estrogen receptor α and β in modulating urothelial cell proliferation publication-title: Endocr Relat Cancer – volume: 36 start-page: 32510 year: 2002 end-page: 5 article-title: Raloxifen, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU‐PR1 human cancer cells publication-title: J Biol Chem – volume: 44 start-page: 4560 year: 1984 end-page: 73 article-title: Characterization of a human, sex steroid‐responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice publication-title: Cancer Res – volume: 64 start-page: 383 year: 2004 end-page: 8 article-title: Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer publication-title: Urology – volume: 8 start-page: 7 year: 2008 article-title: Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospodin‐1 publication-title: BMC Urol – volume: 69 start-page: 1221 year: 2007 end-page: 6 article-title: Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma publication-title: Urology – volume: 25 start-page: 161 year: 1985 end-page: 3 article-title: Androgen receptors in bladder tumors publication-title: Urology – volume: 28 start-page: 409 year: 2010 end-page: 28 article-title: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium publication-title: Urol Oncol – volume: 115 start-page: 68 year: 2009 end-page: 74 article-title: Sex and racial differences in bladder cancer presentation and mortality in the US publication-title: Cancer – volume: 28 start-page: 401 year: 1986 end-page: 3 article-title: Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans publication-title: Urology – volume: 166 start-page: 674 year: 2001 end-page: 7 article-title: Co‐localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat publication-title: J Urol – volume: 99 start-page: 558 year: 2007 end-page: 68 article-title: Promotion of bladder cancer development and progression by androgen receptor signals publication-title: J Natl Cancer Inst – volume: 30 start-page: 556 year: 1997 end-page: 62 article-title: Immunodetection of androgen receptor in human urinary bladder cancer publication-title: Histopathology – volume: 29 start-page: 43 year: 2011 end-page: 51 article-title: Sex‐specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression publication-title: Urol Oncol – volume: 41 start-page: 342 year: 2002 end-page: 5 article-title: Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder publication-title: Eur Urol – volume: 129 start-page: 194 year: 2005 end-page: 9 article-title: Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma publication-title: Arch Pathol Lab Med – volume: 60 start-page: 277 year: 2010 end-page: 300 article-title: Cancer statistics, 2010 publication-title: CA Cancer J Clin – volume: 16 start-page: 123 year: 2009 end-page: 37 article-title: Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder publication-title: Endocr Relat Cancer – volume: 17 start-page: 801 year: 2010 end-page: 10 article-title: Inverse expression of estrogen receptor‐β and nuclear factor‐κB in urinary bladder carcinogenesis publication-title: Int J Urol – volume: 106 start-page: 2610 year: 2006 end-page: 6 article-title: Expression of estrogen receptor‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue publication-title: Cancer – volume: 186 start-page: 165 year: 1998 end-page: 8 article-title: Detection of oestrogen receptors in non‐invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique publication-title: J Pathol – ident: e_1_2_7_28_2 doi: 10.1111/j.1365-2559.2004.01841.x – ident: e_1_2_7_10_2 doi: 10.1093/jnci/djk113 – ident: e_1_2_7_19_2 doi: 10.1016/j.eururo.2009.06.032 – ident: e_1_2_7_30_2 doi: 10.1016/S0302-2838(02)00038-6 – ident: e_1_2_7_29_2 doi: 10.1002/(SICI)1096-9896(1998100)186:2<165::AID-PATH155>3.0.CO;2-Y – ident: e_1_2_7_3_2 doi: 10.1111/j.1440-1827.2009.02477.x – ident: e_1_2_7_6_2 doi: 10.1016/S0022-5347(05)66041-7 – ident: e_1_2_7_4_2 doi: 10.3322/caac.20073 – ident: e_1_2_7_5_2 doi: 10.1002/cncr.23986 – ident: e_1_2_7_33_2 doi: 10.1038/modpathol.2008.34 – ident: e_1_2_7_7_2 doi: 10.1055/s-2002-35951 – ident: e_1_2_7_12_2 doi: 10.1186/1471-2490-8-7 – ident: e_1_2_7_18_2 doi: 10.1677/ERC-08-0124 – ident: e_1_2_7_23_2 doi: 10.1530/ERC-11-0010 – ident: e_1_2_7_13_2 doi: 10.1677/erc.1.01255 – ident: e_1_2_7_8_2 doi: 10.1111/j.1743-6109.2010.01811.x – ident: e_1_2_7_25_2 doi: 10.1016/0090-4295(85)90534-5 – ident: e_1_2_7_17_2 doi: 10.1002/cncr.21945 – volume: 44 start-page: 4560 year: 1984 ident: e_1_2_7_31_2 article-title: Characterization of a human, sex steroid‐responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice publication-title: Cancer Res – ident: e_1_2_7_21_2 doi: 10.1111/j.1464-410X.2010.09834.x – ident: e_1_2_7_24_2 doi: 10.1002/cncr.25502 – ident: e_1_2_7_27_2 doi: 10.1046/j.1365-2559.1997.5610801.x – ident: e_1_2_7_14_2 doi: 10.1016/j.urology.2009.10.041 – ident: e_1_2_7_15_2 doi: 10.1016/j.urology.2004.03.025 – ident: e_1_2_7_32_2 doi: 10.1074/jbc.M202852200 – ident: e_1_2_7_11_2 doi: 10.1016/j.urology.2007.02.041 – ident: e_1_2_7_22_2 doi: 10.1016/j.urolonc.2009.01.033 – ident: e_1_2_7_26_2 doi: 10.1016/0090-4295(86)90073-7 – ident: e_1_2_7_20_2 doi: 10.1111/j.1442-2042.2010.02603.x – volume: 129 start-page: 194 year: 2005 ident: e_1_2_7_16_2 article-title: Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma publication-title: Arch Pathol Lab Med doi: 10.5858/2005-129-194-EREIPU – ident: e_1_2_7_9_2 doi: 10.1158/0008-5472.CAN-05-3530 – ident: e_1_2_7_2_2 doi: 10.1016/j.urolonc.2010.04.003 |
| SSID | ssj0014665 |
| Score | 2.4664028 |
| Snippet | What's known on the subject? and What does the study add?
Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour... What's known on the subject? and What does the study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis and tumour... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1716 |
| SubjectTerms | Adult Aged Aged, 80 and over androgen receptor Biological and medical sciences Bladder cancer bladder tumour Carcinoma - metabolism Carcinoma - pathology Carcinoma - surgery Cohort Studies Female Humans immunohistochemistry Male Medical research Medical sciences Middle Aged Mortality Neoplasm Invasiveness Neoplasm Staging Nephrology. Urinary tract diseases oestrogen receptor Prognosis progression Receptors, Androgen - metabolism Receptors, Estrogen - metabolism recurrence Tumors Tumors of the urinary system Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urothelium - metabolism Urothelium - pathology |
| Title | Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10706.x https://www.ncbi.nlm.nih.gov/pubmed/22221549 https://www.proquest.com/docview/1353349543 https://www.proquest.com/docview/1011846974 |
| Volume | 109 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBajgzEY7X7PXRc02KuDEv2I_dhsDaXQPYwF8mYkW4bSzAlxAqX0j-93luPh0ocyFvJgKzkRne-k76JPd4x9G6uJ8S6RscmViFWiVZxinYhLI7G6iQJvOo18-dOcz9XFQi9a_hOdhQn5Ibo_3MgzmvmaHNy6-qGTq1iNxCJk4kQgI8yQ8CRRtwgf_eoySeGrTVXJIALY3if1PNpRb6V6tbY1lFaGahePwdE-um2Wp9kRu94PLLBSroe7rRvmtw9yPv6fkb9mhy2K5afB7N6wZ756y15ctvv079jd2U1LsK34quSWsiLAUumCrzCccIfJ1q-p2k_TfrWtObHFqhWljuZELCEaE1klv6r4bkNnxZZwF14R693Wf6hrtHHaMMBouFvSNLp5z-azs9_fz-O2zkOcI_gxcTnyWBSBNQTAGgCUSYyTVpVprmFhXifF2AufF6p0TqfaJcqlNhXWJ74EgCnlB3ZQrSr_Cc904go50YiTAA3RoRPaSikKa5JxqlMRscn-mWZ5mwSdanEss14wpDJSbkbKzRrlZjcRG3WS65AI5Akyg57ZdIKIOUcJ4pqIneztKGvnjjqjSiQScauSEfvafQyvp60cCxXvaiLmITQ3CAYj9jHY39_O8aLEexhrY0VP_rnZ9GLeXB7_s-Rn9hLt48ClO2EH283OfwFq27oBe346_TGdDRq_vAfCqTL_ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBajhW0w9rudt67TYK8OSiwp9mM3WrKu6cNoIG_CsmUoy5wQJ1DG_vh9JzkeLn0oYyEPtuMTufOd7jvrdMfYp5Eca2fTJNaFFLFMlYwz-Im40gm8myjxpd3I00s9mcnzuZq37YBoL0yoD9G9cCPL8PM1GTi9kL5t5TKWQzEPpTgRyQg9AKDcpwbfPr763tWSwr2-r2SgAXDvp_XcOVLPVz1Z5Q3EVoV-F3cB0j6-9Q7q7Blb7FgLeSk_BtuNHRS_blV9_E-8P2dPWyDLT4LmvWAPXP2SPZy2S_Wv2O_TmzbHtubLiudUGAHKSgd8CX7CGeZbt6KGP_769abhlDBWL6l6NKfcEspkIsXk1zXfrmm72AIWw2tKfM-bnzQ0rnFaMwA73C5oJl2_ZrOz06svk7ht9RAXiH90XA0d_CLghgBeA4bSqbZJLqusUFAyp9Jy5IQrSllZqzJlU2mzPBO5S10FDFMlB2yvXtbuDR7q2JbJWCFUAjrEgFaoPElEmet0lKlMRGy8e6imaOugUzuOhenFQ9KQcA0J13jhmpuIDTvKVagFcg-a457edIQIO4cpQpuIHe0UybTTR2OoGUmC0FUmEfvY_QzDp9WcHCLeNpSbh-hcIx6M2GFQwL-D40O198CrV6N7_13z-XzmD9_-M-UH9mhyNb0wF18vv71jj3HPKKTWHbG9zXrr3gPEbeyxN84_RP01qA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBajgzIY3e_VW9tpsFcHJZIV-XFbG7puLWMskDdh2TKUZk6IEyhjf_y-sxwPlz6UsuAHx_EJ3_lO9110umPsw0iNtXdGxjpXIlYmUXEKPxGXWsK7iQIH7UY-v9CnU3U2S2Zt_hPthQn1Ibo_3MgymvmaDHxZlDeNXMVqKGahEicCGaEHwJMPlRaGNPz4R1dKCvc2bSUDDXB7P6vn1pF6rurxMqshtTK0u7gNj_bhbeOfJk_Y1ZazkJZyNdis3SD_faPo4_9h_Snba2Es_xj07hl74KvnbPe8Xah_wf6cXLcZthVflDyjsghQVTrhC7ATvmG29Utq99Ncv1zXnNLFqgXVjuaUWUJ5TKSW_LLimxVtFpvDXnhFae9Z_YuGxjVOKwbghrs5zaOrl2w6Ofn5-TRuGz3EOaIfHZdDD68IsCGA1oCgtNFOZqpM8wQq5hNTjLzweaFK55I0cUa5NEtF5o0vgWBK-YrtVIvK7-Odjl0hxwkCJWBDDOhEkkkpikybUZqkImLj7Tu1eVsFnZpxzG0vGlKWhGtJuLYRrr2O2LCjXIZKIHegOeqpTUeIoHNoENhE7GCrR7adPGpLrUgkAlclI_a--xlmT2s5GUS8qSkzD7G5RjQYsddB__4Njg9V3gOvjRbd-XHtp7Npc_rm3pTv2O7344n99uXi61v2CLeMQl7dAdtZrzb-EAhu7Y4a0_wLhd80YA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+androgen+and+oestrogen+receptors+and+its+prognostic+significance+in+urothelial+neoplasm+of+the+urinary+bladder&rft.jtitle=BJU+international&rft.au=Miyamoto%2C+Hiroshi&rft.au=Yao%2C+Jorge+L&rft.au=Chaux%2C+Alcides&rft.au=Zheng%2C+Yichun&rft.date=2012-06-01&rft.eissn=1464-410X&rft.volume=109&rft.issue=11&rft.spage=1716&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10706.x&rft_id=info%3Apmid%2F22221549&rft.externalDocID=22221549 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |